Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod Alone and in Combination With Omeprazole in sGERD
NCT00149851Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tegaserod in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Novartis. Primary endpoints: Proportion of patients experiencing resolution of heart-burn at 4 weeks and Decreasing frequency of regurgitation at 4 weeks. Started Jan 2004; status: completed.
02
Drugs
tegaserod
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00149851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149851.